Short answer
Tonix Pharmaceuticals Holding Corp. (TNXP) filed an 8-K current report with the SEC on June 8, 2026 reporting Item 7.01 (Regulation FD Disclosure), Item 8.01 (Other Events). Boilerplate Regulation FD disclaimer limiting Exchange Act Section 18 liability.
Tonix Pharmaceuticals Holding Corp. 8-K event analysis
AI summary of each reported item and its exhibits
Item 7.01 · Regulation FD Disclosure
- Boilerplate Regulation FD disclaimer limiting Exchange Act Section 18 liability
- Disclosure not incorporated by reference into other SEC filings unless expressly stated
Item 8.01 · Other Events
- GPO agreement effective June 1, 2026, expanding TONMYA commercial coverage to approximately 17 million U.S. insured individuals
- Standard utilization management criteria may improve prescribing access versus more restrictive coverage requirements
- Existing Medicaid availability in most states reaches approximately 75 million beneficiaries
- Broader payer access strengthens TONMYA’s commercial launch potential, though coverage does not guarantee prescriptions or revenue
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Tonix Pharmaceuticals Holding Corp. 8-K filings
Get the next TNXP 8-K as it lands
Follow TNXP for push alerts, or ask the research agent what this filing means.